- Home
- CABO vs AKRO Comparison
CABO vs AKRO Comparison
Compare CABO & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABO
- AKRO
- Stock Information
- Founded
- CABO 1980
- AKRO 2017
- Country
- CABO United States
- AKRO United States
- Employees
- CABO N/A
- AKRO N/A
- Industry
- CABO Cable & Other Pay Television Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- CABO Telecommunications
- AKRO Health Care
- Exchange
- CABO Nasdaq
- AKRO Nasdaq
- Market Cap
- CABO 717.5M
- AKRO 3.9B
- IPO Year
- CABO N/A
- AKRO 2019
- Fundamental
- Price
- CABO $124.47
- AKRO $51.69
- Analyst Decision
- CABO Hold
- AKRO Strong Buy
- Analyst Count
- CABO 3
- AKRO 6
- Target Price
- CABO $231.00
- AKRO $82.50
- AVG Volume (30 Days)
- CABO 215.6K
- AKRO 1.6M
- Earning Date
- CABO 07-31-2025
- AKRO 08-08-2025
- Dividend Yield
- CABO 7.10%
- AKRO N/A
- EPS Growth
- CABO N/A
- AKRO N/A
- EPS
- CABO N/A
- AKRO N/A
- Revenue
- CABO $1,555,831,000.00
- AKRO N/A
- Revenue This Year
- CABO N/A
- AKRO N/A
- Revenue Next Year
- CABO N/A
- AKRO N/A
- P/E Ratio
- CABO N/A
- AKRO N/A
- Revenue Growth
- CABO N/A
- AKRO N/A
- 52 Week Low
- CABO $121.37
- AKRO $21.34
- 52 Week High
- CABO $437.00
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- CABO 36.92
- AKRO 45.35
- Support Level
- CABO $126.35
- AKRO $50.13
- Resistance Level
- CABO $137.88
- AKRO $53.60
- Average True Range (ATR)
- CABO 6.48
- AKRO 2.03
- MACD
- CABO 1.54
- AKRO -0.83
- Stochastic Oscillator
- CABO 11.85
- AKRO 6.37
About CABO Cable One Inc.
Cable One Inc. is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. From a product standpoint, the majority of revenue comes from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols. Cable One Inc. owns its telecommunications infrastructure.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.